Clene Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
5analysts covering
FY Revenue (est.)
$207.4Knext fiscal year
FY EPS (est.)
-$1.41next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Phase 3 Confirmatory Trial Start | 31 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly5.9MTarget: Maintain above $2.0 million unrestricted cash covenant
Quarterly Net Loss Quarterly-8.1MTarget: Narrowing losses through cost-saving initiatives
Common Stock Shares Outstanding Quarterly12.8MTarget: Minimize dilution from milestone-based warrant tranches
Watch Items
- NDA Submission for CNM-Au8 in ALSTrigger: Submission to the FDA under the Subpart H accelerated approval pathwayAction: Monitor FDA acceptance decision and potential unlock of milestone-based warrant tranches
- Going Concern Status and Cash RunwayTrigger: Cash runway projected into Q4 2026Action: Track additional capital raises, underwritten offerings, or strategic partnerships to extend runway into 2027
- Phase 3 Confirmatory Trial InitiationTrigger: Planned initiation of Phase 3 confirmatory study in ALSAction: Verify trial start in Q1 2027 as requested by the FDA
Research as of 19 Jun 2026